Project Grant R43AR086088
Award Date 9/18/25
Completion Date 8/31/26
Dollars Obligated $297K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to advance the development of a novel oral, first-in-class therapeutic for the treatment of rheumatoid arthritis (RA). The project aims to conduct pharmacokinetic and safety studies, characterize the effects of the lead compound on human fibroblast-like...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $312,323 Project Grant to Knoubis Bio Inc. under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The grant supports the development of a novel bispecific biologic therapy for rheumatoid arthritis (RA) that targets the transmembrane tyrosine phosphatase PTPRS. The key activities under this Phase I project include conducting pharmacokinetic studies in mice...
- This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
- The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $529,616 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to Brigham & Women's Hospital Inc. to conduct research on the role of Notch signaling and fibrosis in treatment-resistant rheumatoid arthritis. The project aims to define the molecular mechanisms by which Notch signaling regulates transforming growth factor beta (TGF-β) signaling in...
- This federal Project Grant award of $646,506 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) is supporting the development of dual-action nanoparticle-loaded microparticles for the treatment of osteoarthritis (OA). The research aims to create innovative nanoparticle-based therapeutics that can stimulate the anabolic activity of chondroprogenitors to enhance cartilage...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is supporting the development of an intraarticular (injectable) Wnt inhibitor therapy for the treatment of osteoarthritis (OA). OA is a common and debilitating joint disease affecting nearly 21 million people in the U.S. The $314,363 award, made on September 16, 2025, will fund the...
- This $527,760 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research on the role of endogenous retroviruses in autoimmune diseases like rheumatoid arthritis (RA). The award to the University of California, San Francisco will support a study to identify the specific antigens and mechanisms by which self-reactive T cells evade tolerance and...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to investigate the molecular mechanisms of TAK1 regulation in rheumatoid arthritis (RA). The $1,407,925 award to Washington State University, effective August 12, 2025 through July 31, 2028, will focus on understanding how TAK1, a key signaling mediator, regulates the...
- This federal Project Grant award of $1,950,412.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846), to Wake Forest University Health Sciences. The funding supports research to define how the IRE1A-XBP1-NUPR1 signaling axis in immune cells and chondrocytes contributes to synovial inflammation, cartilage damage, and osteoarthritis pain. The...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $170,101 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, for a project titled "Dissecting the Spatial Heterogeneity of Synovial Inflammation in Rheumatoid Arthritis". The project aims to systematically characterize the spatial heterogeneity of synovial inflammation in rheumatoid...